Explore the words cloud of the miRCaP project. It provides you a very rough idea of what is the project "miRCaP" about.
The following table provides information about the project.
Coordinator |
HUMANITAS MIRASOLE SPA
Organization address contact info |
Coordinator Country | Italy [IT] |
Total cost | 150˙000 € |
EC max contribution | 150˙000 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2015-PoC |
Funding Scheme | ERC-POC |
Starting year | 2016 |
Duration (year-month-day) | from 2016-12-01 to 2018-05-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | HUMANITAS MIRASOLE SPA | IT (ROZZANO (MI)) | coordinator | 150˙000.00 |
Innovative nanoparticle formulation for a miR-133 based treatment of cardiac hypertrophy
Cardiovascular diseases (CDs) are growing problems worldwide, affecting as much as 1% of the population. The causes include ischemic, toxic, genetic, post-inflammatory and structural defects; often multiple etiologies are present within an individual patient germane to the contraction failing, resulting in a mortality of ca. 50% within 5 years from diagnosis. Unexpected roles have been unveiled for microRNAs, important key-players in such pathogenesis, able to regulate levels of genes that govern cell remodeling. In line with this, development of microRNA-based drugs aimed at preventing stress-induced dysregulations of microRNA levels has attracted remarkable attention as potential candidates for therapeutic applications. Particular attention is paid to the miR-133, a muscle-specific microRNA, which has been found inversely related to pathological cardiac hypertrophy. However, a key challenge of microRNA-based drugs relies on delivery efficiency, toxicity and specificity. Here, we propose to generate innovative and effective therapeutic strategies based on the development of novel biocompatible and bioresorbable calcium phosphate nanoparticles (CaP-NP) for carrying miR-133 selectively to the heart. Our aim is to functionalize CaP-NPs for a selective delivery of the therapeutic miR133 to the pathological heart. The development of a novel approach based on CaP-NPs might be an efficient cardiac drug-delivery system for a specific release of miR-133. The successful outcome of this proposal will provide a relevant preclinical proof-of-concept necessary for 1) the development of additional Intellectual Properties, 2) the translation into a commercial strategy and business case, and 3) the identification of strategic partners and venture capitalist.
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Irene Salamon, Gloria Saccani Jotti, Gianluigi Condorelli The long noncoding RNA landscape in cardiovascular disease published pages: 1, ISSN: 0268-4705, DOI: 10.1097/HCO.0000000000000507 |
Current Opinion in Cardiology | 2019-06-13 |
2018 |
Serge Masson, Sandor Batkai, Julia Beermann, Christian Bär, Angelika Pfanne, Sabrina Thum, Michela Magnoli, Giovanna Balconi, Gian Luigi Nicolosi, Luigi Tavazzi, Roberto Latini, Thomas Thum Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure published pages: 78-85, ISSN: 1388-9842, DOI: 10.1002/ejhf.961 |
European Journal of Heart Failure 20/1 | 2019-06-13 |
2017 |
Roberto Papait, Simone Serio, Christina Pagiatakis, Francesca Rusconi, Pierluigi Carullo, Marta Mazzola, Nicolò Salvarani, Michele Miragoli, Gianluigi Condorelli Histone Methyltransferase G9a Is Required for Cardiomyocyte Homeostasis and Hypertrophy published pages: 1233-1246, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.117.028561 |
Circulation 136/13 | 2019-06-13 |
2017 |
Veronica Larcher, Paolo Kunderfranco, Marco Vacchiano, Pierluigi Carullo, Marco Erreni, Irene Salamon, Federico Simone Colombo, Enrico Lugli, Marta Mazzola, Achille Anselmo, Gianluigi Condorelli An autofluorescence-based method for the isolation of highly purified ventricular cardiomyocytes published pages: 409-416, ISSN: 0008-6363, DOI: 10.1093/cvr/cvx239 |
Cardiovascular Research 114/3 | 2019-06-13 |
2018 |
Leonardo Elia, Paolo Kunderfranco, Pierluigi Carullo, Marco Vacchiano, Floriana Maria Farina, Ignacio Fernando Hall, Stefano Mantero, Cristina Panico, Roberto Papait, Gianluigi Condorelli, Manuela Quintavalle UHRF1 epigenetically orchestrates smooth muscle cell plasticity in arterial disease published pages: 2473-2486, ISSN: 0021-9738, DOI: 10.1172/JCI96121 |
Journal of Clinical Investigation 128/6 | 2019-06-13 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIRCAP" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MIRCAP" are provided by the European Opendata Portal: CORDIS opendata.